|
|
| | Benserazide Hydrochloride impurity C Basic information |
| Product Name: | Benserazide Hydrochloride impurity C | | Synonyms: | Benserazide Hydrochloride impurity C;Benserazide EP Impurity C HCl;CSRM617 hydrochloride
(CSRM-617);(2,3,4-Trihydroxyphenyl)methylene]hydrazide-serine Hydrochloride;2-amino-3-hydroxy-N'-(2,3,4-trihydroxybenzylidene)propanehydrazide hydrochloride;Benzylhydrazone hydrochloride;Benserazide EP Impurity C(Hydrochloride);Benserazide P-1 | | CAS: | 1353749-74-2 | | MF: | C10H14ClN3O5 | | MW: | 291.69 | | EINECS: | 940-411-0 | | Product Categories: | | | Mol File: | 1353749-74-2.mol |  |
| | Benserazide Hydrochloride impurity C Chemical Properties |
| Melting point | >177°C (dec.) | | density | 1.68g/cm3 at 21℃ | | storage temp. | Hygroscopic, Refrigerator, under inert atmosphere | | solubility | DMSO (Slightly), Water (Slightly, Sonicated) | | form | Solid | | color | Off-White to Pale Beige | | LogP | 1 at 40℃ and pH6.5 |
| | Benserazide Hydrochloride impurity C Usage And Synthesis |
| Uses | [(2,3,4-Trihydroxyphenyl)methylene]hydrazide-serine Hydrochloride is an impurity of Benserazide (B120505) which is a drug which in combination with dopamine precursor Levodopa (D533751) is used in the management of Parkinson’s disease. | | in vivo | CSRM617 (50 mg/kg; p.o.; daily, for 20 d) inhibits tumor growth in SCID mice with 22Rv1 xenograft[1]. | Animal Model: | SCID mice with 22Rv1 xenograft[1] | | Dosage: | 50 mg/kg | | Administration: | Oral administration; daily, for 20 days | | Result: | Elicited a significant reduction in the onset and growth of diffuse metastases. |
|
| | Benserazide Hydrochloride impurity C Preparation Products And Raw materials |
|